The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Ian D. Schnadig
No relevant relationships to disclose
Menaka Bhor
No relevant relationships to disclose
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Daniel Hennessy
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Leonardo V. Nicacio
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
William R. Berry
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Thomas E. Hutson
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Mark T. Fleming
Consultant or Advisory Role - Sanofi
C. Lance Cowey
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Shanmugapriya Saravanan
No relevant relationships to disclose
Rahul Dhanda
No relevant relationships to disclose
Guru Sonpavde
Consultant or Advisory Role - Astellas Pharma; Dendreon
Honoraria - Janssen Pharmaceutical ; Sanofi
Research Funding - Sanofi